The AngioJet DVX Thrombectomy catheter is specially engineered for powerful thrombus removal in peripheral arteries. The design of the DVX catheter leverages the power of the AngioJet System’s exclusive Cross-Stream® action by increasing the clearing profile in larger peripheral vessels. The DVX catheter was developed in response to the need for an effective method of removing older, chronic clot — especially problematic in larger peripheral arteries.

AngioJet DVX Rheolytic Thrombectomy catheter is intended for use with the AngioJet System in breaking apart and removing thrombus from infra-inguinal peripheral arteries ≥ 3mm in diameter. The AngioJet System includes several catheter models that are marketed for thrombectomy of coronary arteries and bypass grafts, AV access conduits, and peripheral arteries. See product Information for Use for specific and complete prescribing information.

Operation of the Catheter may cause hemolysis. Hemolysis indicators in the blood should be monitored if total operation time exceeds 8 minutes or if operation in a flowing blood field exceeds 4 minutes. Excessive hemolysis may require blood transfusion. In investigational clinical studies, hemolysis induced by AngioJet System operation was not associated with any significant systemic response.

The AngioJet System includes several catheter models that are marketed in the U.S. for thrombectomy of coronary arteries and bypass grafts, A.V. access conduits, and peripheral arteries. See product Information for Use for specific and complete prescribing information.

AngioJet, Rheolytic, Cross-Stream, Xpeedior, Tru-Seal, Spiroflex, XMI, AVX, XVG, DVX and Power Pulse are trademarks of Possis Medical, Inc.

1612-001 02 4/07